Aurinia Pharmaceuticals (TSE:AUP) Shares Down 3.5%

Aurinia Pharmaceuticals Inc. (TSE:AUPGet Free Report) (NASDAQ:AUPH)’s stock price traded down 3.5% on Monday . The company traded as low as C$16.41 and last traded at C$16.76. 4,611,683 shares traded hands during mid-day trading, an increase of 1,906% from the average session volume of 229,895 shares. The stock had previously closed at C$17.37.

Aurinia Pharmaceuticals Stock Performance

The stock has a market capitalization of C$2.15 billion and a P/E ratio of -11.32. The firm has a fifty day moving average of C$16.76. The company has a current ratio of 11.93, a quick ratio of 11.02 and a debt-to-equity ratio of 2.69.

Aurinia Pharmaceuticals Company Profile

(Get Free Report)

Aurinia Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.

Read More

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.